Comparison of Vascular Effects After Therapy With Irbesartan and Atorvastatin.

This study has been completed.
Sponsor:
Information provided by:
Technische Universität Dresden
ClinicalTrials.gov Identifier:
NCT00154024
First received: September 8, 2005
Last updated: September 27, 2006
Last verified: July 2006
  Purpose

Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.


Condition Intervention
Healthy Subjects
Drug: atorvastatin
Drug: irbesartan

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Characterization of Local Vascular Effects of Angiotensin II and Histamine After Treatment With Irbesartan and Atorvastatin.

Resource links provided by NLM:


Further study details as provided by Technische Universität Dresden:

Primary Outcome Measures:
  • vascular responses after treatment.

Study Start Date: March 2003
Estimated Study Completion Date: October 2006
Detailed Description:

Vascular responses to angiotensin II and histamine are compared before and after 30 days of systemic treatment with either irbesartan 150 mg or atorvastatin 20 mg.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy subjects
  • no relevant disease
  • amendment: hypercholesterolaemic subjects

Exclusion Criteria:

  • any relevant disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00154024

Locations
Germany
Institute of Clinical Pharmacology, Medical Faculty, University of Technology
Dresden, Germany, 01307
Sponsors and Collaborators
Technische Universität Dresden
Investigators
Study Chair: Wilhelm Kirch, MD Institute of Clinical Pharmacology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00154024     History of Changes
Other Study ID Numbers: IKPD 03-02
Study First Received: September 8, 2005
Last Updated: September 27, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by Technische Universität Dresden:
venoconstriction
venodilation
pleiotropic effects

Additional relevant MeSH terms:
Atorvastatin
Irbesartan
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Anticholesteremic Agents
Antihypertensive Agents
Antimetabolites
Cardiovascular Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on October 22, 2014